Alzheimer Disease

Can targeting tau slow cognitive decline in Alzheimer's disease?

Diranersen, an investigational antisense oligonucleotide, reduced tau levels and showed a corresponding slowdown in cognitive decline.

Pupil Dilation: A Window into Synesthesia's Perceptual Quality

Pupil size changes reflect the vividness and automaticity of synesthetic experiences, offering an objective measure of subjective perception.

Ecopipam for Tourette Syndrome: Did it deliver on its promise?

Ecopipam significantly reduced tic severity in Tourette syndrome patients, but its safety profile warrants careful consideration for long-term use.

Football Headers Linked to Cognitive Decline, Neurodegeneration

Repeated head impacts from football headers correlate with increased risk of cognitive impairment and neurodegenerative disease, particularly in former professional players.

Roche Halts Huntington's Gene-Silencing Programs

Roche has ended its gene-silencing programs for Huntington's disease, including tominersen, after clinical trials failed to show benefit or raised safety concerns.

Katie Couric's Transient Global Amnesia: A 'Big, Black Hole' Event

Katie Couric recently described an episode of transient global amnesia, a sudden, temporary loss of memory that can be alarming but is typically benign.

AXS-05 Reduces Agitation in Alzheimer's Disease Patients

AXS-05 significantly reduced agitation in patients with Alzheimer's disease, demonstrating efficacy and a favorable safety profile in the ACCORD-2 trial.

Alzheimer's Research Lays Foundation for Precision Medicine

New insights into Alzheimer's disease pathophysiology are establishing a framework for targeted therapies, moving beyond amyloid-centric approaches.

Creatine Supplementation: Limited Evidence for Brain Health Benefits

Creatine supplementation shows inconsistent and largely unproven benefits for brain health in healthy adults, with some promise in specific populations facing metabolic stress.